title: Effect of p53 status on tumor response to antiangiogenic therapy.
abstract: The p53 tumor suppressor gene is inactivated in the majority of human cancers. Tumor cells deficient in p53 display a diminished rate of apoptosis under hypoxic conditions, a circumstance that might reduce their reliance on vascular supply, and hence their responsiveness to antiangiogenic therapy. Here, we report that mice bearing tumors derived from p53(-/-) HCT116 human colorectal cancer cells were less responsive to antiangiogenic combination therapy than mice bearing isogenic p53(+/+) tumors. Thus, although antiangiogenic therapy targets genetically stable endothelial cells in the tumor vasculature, genetic alterations that decrease the vascular dependence of tumor cells can influence the therapeutic response of tumors to this therapy.
authors.affiliation: Sunnybrook and Women's College Health Sciences Centre, Molecular and Cellular Biology Research, Room S-218, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5.
authors.forename: Joanne L
authors.initials: JL
authors.lastname: Yu
authors.forename: Janusz W
authors.initials: JW
authors.lastname: Rak
authors.forename: Brenda L
authors.initials: BL
authors.lastname: Coomber
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Hicklin
authors.forename: Robert S
authors.initials: RS
authors.lastname: Kerbel
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis; D015687:Cell Hypoxia; D002470:Cell Survival; D015179:Colorectal Neoplasms; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins / Q000235:genetics / Q000378:metabolism; D017353:Gene Deletion; D020868:Gene Silencing; D016158:Genes, p53; D006801:Humans; D020287:In Situ Nick-End Labeling; D051379:Mice; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000098:blood supply / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D020794:Receptor Protein-Tyrosine Kinases / Q000276:immunology; D017978:Receptors, Growth Factor / Q000276:immunology; D040262:Receptors, Vascular Endothelial Growth Factor; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D014747:Vinblastine / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D000906:Antibodies; C493956:CDKN1A protein, human; C493957:Cdkn1a protein, mouse; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D017978:Receptors, Growth Factor; D016159:Tumor Suppressor Protein p53; D014747:Vinblastine; D020794:Receptor Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor